Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Peripheral membrane protein Cytoplasmic vesicle membrane Peripheral membrane protein Note=Predominantly observed in association with the plasma membrane of soma and in neurites, both axons and dendrites. May be associated with vesicular structures (By similarity). |
Domain |
PF00069 Protein kinase domain |
Function |
Does not appear to have detectable kinase activity. |
Biological Process | - |
Molecular Function |
GO:0005516 calmodulin binding |
Cellular Component |
GO:0030659 cytoplasmic vesicle membrane |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CAMKV and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CAMKV in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CAMKV in various data sets.
|
Points in the above scatter plot represent the mutation difference of CAMKV in various data sets.
|
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CAMKV. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CAMKV. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CAMKV. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CAMKV. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CAMKV expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CAMKV and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CAMKV |
Name | CaM kinase-like vesicle-associated |
Aliases | MGC8407; VACAMKL; 1G5; vesicle-associated calmodulin-binding protein; CaM kinase-like vesicle-associated pro ...... |
Chromosomal Location | 3p21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CAMKV collected from DrugBank database. |
There is no record. |